National HIV/AIDS Research Center, Istituto Superiore di Sanità, V.le Regina Elena 299, 00161, Rome, Italy.
Core Facilities, Istituto Superiore di Sanità, Rome, Italy.
Sci Rep. 2023 Sep 9;13(1):14908. doi: 10.1038/s41598-023-41814-x.
HBV/HCV co-infection is common in HIV-1-infected prisoners. To investigate the characteristics of HIV co-infections, and to evaluate the molecular heterogeneity of HIV, HBV and HCV in prisoners, we carried-out a multicenter cross-sectional study, including 65 HIV-1-infected inmates enrolled in 5 Italian detention centers during the period 2017-2019. HIV-1 subtyping showed that 77.1% of inmates were infected with B subtype and 22.9% with non-B subtypes. Italian nationals were all infected with subtype B (93.1%), except two individuals, one infected with the recombinant form CRF72_BF1, and the other with the HIV-1 sub-subtype A6, both previously not identified in inmates of Italian nationality. Non-Italian nationals were infected with subtype B (52.6%), CRFs (36.8%) and sub-subtypes A1 and A3 (5.2%). HIV variants carrying resistance mutations to NRTI, NNRTI, PI and InSTI were found in 7 inmates, 4 of which were never exposed to the relevant classes of drugs associated with these mutations. HBV and/or HCV co-infections markers were found in 49/65 (75.4%) inmates, while 27/65 (41.5%) showed markers of both HBV and HCV coinfection. Further, Italian nationals showed a significant higher presence of HCV markers as compared to non-Italian nationals (p = 0.0001). Finally, HCV phylogenetic analysis performed in 18 inmates revealed the presence of HCV subtypes 1a, 3a, 4d (66.6%, 16.7% and 16.7%, respectively). Our data suggest the need to monitor HIV, HBV and HCV infections in prisons in order to prevent spreading of these viruses both in jails and in the general population, and to implement effective public health programs that limit the circulation of different genetic forms as well as of viral variants with mutations conferring resistance to treatment.
HBV/HCV 合并感染在感染 HIV-1 的囚犯中很常见。为了研究 HIV 合并感染的特征,并评估 HIV、HBV 和 HCV 在囚犯中的分子异质性,我们进行了一项多中心横断面研究,包括 2017 年至 2019 年期间在 5 个意大利拘留中心登记的 65 名感染 HIV-1 的囚犯。HIV-1 亚型分析显示,77.1%的囚犯感染 B 亚型,22.9%感染非 B 亚型。意大利国民均感染 B 亚型(93.1%),除了 2 人,其中 1 人感染重组型 CRF72_BF1,另 1 人感染之前在意大利籍囚犯中未发现的 HIV-1 亚亚型 A6。非意大利籍国民感染 B 亚型(52.6%)、CRF(36.8%)和亚亚型 A1 和 A3(5.2%)。在 7 名囚犯中发现了对 NRTI、NNRTI、PI 和 InSTI 耐药的 HIV 变异株,其中 4 名囚犯从未接触过与这些变异株相关的药物。在 65 名囚犯中有 49 名(75.4%)发现了 HBV 和/或 HCV 合并感染标志物,而 27 名(41.5%)同时有 HBV 和 HCV 合并感染标志物。此外,意大利国民的 HCV 标志物阳性率显著高于非意大利国民(p=0.0001)。最后,对 18 名囚犯进行的 HCV 系统进化分析显示,存在 HCV 1a、3a 和 4d 亚型(分别为 66.6%、16.7%和 16.7%)。我们的数据表明,需要在监狱中监测 HIV、HBV 和 HCV 感染,以防止这些病毒在监狱和普通人群中传播,并实施有效的公共卫生计划,限制不同遗传形式以及具有治疗耐药性变异的病毒变异的传播。